New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|June 28, 2019
Supplements and Featured Publications
- Expert Panel: Access to Evidence-based Therapies Is Necessary to Support Individualized Treatment of HIV
Expert Panel: Access to Evidence-based Therapies Is Necessary to Support Individualized Treatment of HIV
Advertisement
This opinion paper, developed by a multidisciplinary panel of HIV experts in 2019 reflects the group’s consensus on recommendations for various stakeholders who work to improve HIV care, including population health decision-makers (such as formulary committees, pharmacy benefit managers, and clinical advisors), advocacy organizations, and local, state, and federal policy makers.
Advertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
5